Evidence map›Paper›PMID 16055710›Full record

ArticleMolecular and cellular biology2005

Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.

Guillaume Bossis, Cécile E Malnou, Rosa Farras, Elisabetta Andermarcher, Robert Hipskind, Manuel Rodriguez, Darja Schmidt, Stefan Muller, Isabelle Jariel-Encontre, Marc Piechaczyk

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 186 citations in OpenAlex.

  1. Article
  2. Article
  3. Innate immunity: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review
  4. Review
  5. Article
  6. Synergistic roles of NFATc1 and c-Jun in immunomodulation.Biochemistry and biophysics reports · 2025
    Review
  7. Immune regulation by the SUMO family.Nature reviews. Immunology · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Contribution of the Transcription Factors Sp1/Sp3 and AP-1 toInternational journal of molecular sciences · 2021
    Article
  17. Review
  18. Review
  19. Article
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Guillaume BossisInstitute of Molecular Genetics of Montpellier, UMR5535/IFR122, CNRS 1919, France.
Cécile E Malnou
Rosa Farras
Elisabetta Andermarcher
Robert Hipskind
Manuel Rodriguez
Darja Schmidt
Stefan Muller
Isabelle Jariel-Encontre
Marc Piechaczyk
Centre National de la Recherche Scientifique · FRMax Planck Institute of Biochemistry · DEUniversity of St Andrews · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inducible transcriptional complex AP-1, composed of c-Fos and c-Jun proteins, is crucial for cell adaptation to many environmental changes. While its mechanisms of activation have been extensively studied, how its activity is restrained is poorly understood. We report here that lysine 265 of c-Fos is conjugated by the peptidic posttranslational modifiers SUMO-1, SUMO-2, and SUMO-3 and that c-Jun can be sumoylated on lysine 257 as well as on the previously described lysine 229. Sumoylation of c-Fos preferentially occurs in the context of c-Jun/c-Fos heterodimers. Using nonsumoylatable mutants of c-Fos and c-Jun as well as a chimeric protein mimicking sumoylated c-Fos, we show that sumoylation entails lower AP-1 transactivation activity. Interestingly, single sumoylation at any of the three acceptor sites of the c-Fos/c-Jun dimer is sufficient to substantially reduce transcription activation. The lower activity of sumoylated c-Fos is not due to inhibition of protein entry into the nucleus, accelerated turnover, and intrinsic inability to dimerize or to bind to DNA. Instead, cell fractionation experiments suggest that decreased transcriptional activity of sumoylated c-Fos is associated with specific intranuclear distribution. Interestingly, the phosphorylation of threonine 232 observed upon expression of oncogenically activated Ha-Ras is known to superactivate c-Fos transcriptional activity. We show here that it also inhibits c-Fos sumoylation, revealing a functional antagonism between two posttranslational modifications, each occurring within a different moiety of a bipartite transactivation domain of c-Fos. Finally we report that the sumoylation of c-Fos is a dynamic process that can be reversed via multiple mechanisms. This supports the idea that this modification does not constitute a final inactivation step that necessarily precedes protein degradation.

Indexed as

Down-RegulationGene Expression Regulation, NeoplasticBinding SitesDimerizationGlutathione TransferaseHeLa CellsHumansImmunoblottingImmunoprecipitationKineticsLuciferasesLysineMicroscopy, FluorescenceMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Mutagenesis, Site-DirectedGlutathione TransferaseHRAS protein, humanLuciferasesLysineMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Proto-Oncogene Proteins c-fosProto-Oncogene Proteins c-junProto-Oncogene Proteins p21(ras)Recombinant Fusion ProteinsSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSUMO2 protein, humanThreonineTranscription Factor AP-1

Identifiers

PMID16055710
PMCPMC1190241
OpenAlexW2111833081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.